endocrinology
Type 1 diabetes

Highlights from #ADA2016

Results from the LEADER study showing fewer cardiovascular events in patients treated with liraglutide and an update of the EMPA-REG study identifying renal benefits from empagliflozin were just some of the highlights from the 2016 annual meeting of the American Diabetes Association held in New Orleans this week. The LEADER study, published in the New ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic